Generic medicines have the same efficacy and safety as originators at lower prices;
however, there are concerns with their utilization in Nigeria. Objective was to evaluate …

This report, with a focus on sustainable access to new medicines, reviews policies that affect
medicines throughout their lifecycle (‎ from research and development to disinvestment)‎ …

Results: Information is available from 40 European countries, thereof 28 European Union
Member States, as well as Canada and South Africa. We identified a common method for …

Objectives: Pharmaceutical expenditure has risen rapidly resulting in multiple reforms
across countries. This includes Korea. Review policies and initiatives undertaken in Europe …

The manufacturer of pregabalin has a second use patent covering prescribing for
neuropathic pain: its principal indication. The manufacturer has threatened legal action in …

Introduction: A new pricing policy was introduced in Korea in April 2012 with the aim of
strengthening competition among off-patent drugs by eliminating price gaps between …

Getting the most out of the pharmaceutical budget is critical across all countries as the
financial pressures on healthcare systems intensify. In this paper, we review global practice …

Background Healthcare systems spend considerable proportions of their budgets on
pharmaceutical treatment of hypertension, hyperlipidemia, and diabetes mellitus. From data …

Background There have been concerns in Korea that the availability of cheaper generics
can appreciably increase prescribed volumes thereby negating their beneficial effects on …

Kontinuierliches Monitoring und regelmäßige Analyse von Medikamentenpreisen
unterstützen Entscheidungen zur Weiterentwicklung der Arzneimittelpreispolitik. Ziel der …